Asabys Partners close €180m Sabadell Asabys II Fund 

Barcelona-headquartered VC investor Asabys Partners has closed of its second fund, Sabadell Asabys Health Innovation Investments II (SAHII II) with total commitments of €180m (US$200m), exceeding its initial target of €150m. Similar to Sabadell Asabys Fund I, the Fund II portfolio will include companies within the fields of biopharma, medtech and digital health.

According to Asabys, SAHII II will invest in 12 to 15 companies in line with Asabys’ core strategy of funding biopharma, medical device and digital health companies that develop novel solutions for unmet medical needs building on solid scientific evidence and a clear benefit for patients. SAHII II welcomed new U.S. and international investors in addition to investors from its previous fund, SAHII I, which closed with €117m in commitments. 

The SAHII II fund’s first closing was announced in January 2023 and since then has already invested in five companies: deepull, Orikine Bio, Gradient Denervation Technologies, ALLOX and Augustine Therapeutics. 

Since its inception in 2018, Asabys has raised close to €300m in assets under management, invested in 17 companies, with 3 exits to date. The team is composed of 11 professionals with deep scientific and technical expertise as well as years of track record investing in the industry, backed by a list of venture partners and advisors.